Skip to main content

Ropeginterferon Alfa-2b-njft

Placeholder slot
 (roh-peg-IN-ter-FEER-on AL-fuh …)

This page contains brief information about ropeginterferon alfa-2b-njft and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Besremi
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ropeginterferon alfa-2b-njft is approved to treat:

Ropeginterferon alfa-2b-njft is a recombinant form of peginterferon alfa-2b. Its effects last longer in the body, so it doesn't need to be given as often. For more information that may apply to ropeginterferon alfa-2b-njft, see the Drug Information Summary for Peginterferon Alfa-2b.

Ropeginterferon alfa-2b-njft is also being studied in the treatment of other types of cancer.

More About Ropeginterferon Alfa-2b-njft

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ropeginterferon Alfa-2b-njft - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Immune System Modulators

Clinical Trials Accepting Patients

Find Clinical Trials for Ropeginterferon Alfa-2b - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: